According to BCC Research predictions, the global market for polymerase chain reaction for point-of-care diagnostics is expected to grow from $1.6 billion in 2024 to $2.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.9% over the forecast period (2024 to 2029).
Driving factors for the forecast period are rising demand for point-of-care testing for infectious diseases (e.g., influenza A & B) and sexually transmitted diseases (HIV). Increasing adoption of multiplex testing to diagnose infectious diseases is an additional factor propelling the growth of the market.
Apart from this, in this blog, we will discuss the top leading companies associated with POC Diagnostics.
Incorporated in 1888, Abbott Laboratories, a U.S.-based pharmaceutical and medical device manufacturing company, discovers, develops, manufactures and sells various healthcare products. The company operates business through four segments: Established Pharmaceutical Products, Diagnostics, Nutritional and Medical Devices.
The company offers point-of-care polymerase chain reaction analyzers (PCR) and associated consumables through the Diagnostic Products segment, whose subdivisions are Core Laboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care. The Rapid Diagnostics subsegment caters to the point-of-care PCR market.
Danaher Corp. designs and manufactures a wide range of products for various industries, including healthcare, environmental and industrial. Danaher operates in three segments: Life Sciences, Diagnostics and Biotechnology.
Danaher’s Diagnostics segment offers a broad range of diagnostic solutions, including clinical chemistry, immunoassays, hematology, microbiology, molecular diagnostics and POCT. Brands include Beckman Coulter, Cepheid, Leica Biosystems, Mammotome, HemoCue and Radiometer.